Quantitative Proteomic Analysis Of Faecal Biomarkers For Colon Cancer
Funder
National Health and Medical Research Council
Funding Amount
$562,398.00
Summary
We have identified a number of potential biomarkers present in the stools of patients with colorectal cancer (CRC). We will use quantitative mass spectrometric techniques that we have developed to validate these biomarkers on a large number of faecal samples from patients with CRC and multiple control groups. We believe these studies will lead to a new panel of biomarkers which will improve the detection of early forms of colon cancer, thus reducing death from this disease.
Precision Nanomedicine-based Diagnostics And Therapeutics For Refractory Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$7,329,484.00
Summary
The vast majority of cancer patients die of their disease due to the emergence of drug resistant cancer cells or metastatic disease that is diagnosed at late stages. Our program aims to develop new types of therapy to specifically target aggressive cancers. To detect cancer early and evaluate the effectiveness of cancer therapy, we will develop sensitive diagnostic tools and devices. This research has application to both childhood and adult cancers.
Clinical And Molecular Analyses Of Nodular Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$130,904.00
Summary
There have been very recent advances in our understanding of the biology of melanoma that are now poised to have major impacts in the outcome of patients with this disease. The nodular subtype of melanoma contributes disproportionately to mortality from melanoma. By using the latest molecular techniques to study these melanomas I will identify causative factors, diagnostic features and molecular profiles associated with these poor-prognosis melanomas leading to new approaches in the prevention, ....There have been very recent advances in our understanding of the biology of melanoma that are now poised to have major impacts in the outcome of patients with this disease. The nodular subtype of melanoma contributes disproportionately to mortality from melanoma. By using the latest molecular techniques to study these melanomas I will identify causative factors, diagnostic features and molecular profiles associated with these poor-prognosis melanomas leading to new approaches in the prevention, early detection and treatment of these melanomas.Read moreRead less
Proteomics And Bioinformatics Analyses Of Exosomes And Secretome For The Detection Of Colorectal Cancer Biomarkers
Funder
National Health and Medical Research Council
Funding Amount
$290,032.00
Summary
Cancer of colon and rectum is the most common form of cancer in Australia with 12,000 people diagnosed each year. Of these, more than 4,000 people will die of their disease. Early detection of colorectal cancer (CRC) will significantly improve the patient outcomes and will reduce the human and financial burden this disease places on the community. This research project aim to discover new ways to detect CRC and develop blood-based assays. Validation of these assays will be performed in clinical ....Cancer of colon and rectum is the most common form of cancer in Australia with 12,000 people diagnosed each year. Of these, more than 4,000 people will die of their disease. Early detection of colorectal cancer (CRC) will significantly improve the patient outcomes and will reduce the human and financial burden this disease places on the community. This research project aim to discover new ways to detect CRC and develop blood-based assays. Validation of these assays will be performed in clinical studies using CRC patient samples.Read moreRead less
Proteomic Approaches To Explore The Pathogenesis And Secretomes Of Parasitic Flukes Of Humans
Funder
National Health and Medical Research Council
Funding Amount
$415,320.00
Summary
Ten percent of the human population are at risk of infection with liver, blood and lung flukes. These parasites cause considerable human morbidity and mortality including a strong association with cancer of the bile ducts. Current control efforts rely on drugs, but, reinfection and resistance are a problem. This research is aimed at understanding how these parasites cause disease (particularly how a parasite causes cancer) and the development of vaccines and new drugs.
Skin cancers, including melanoma, present a significant health, social and economic burden in Australia. Despite the rising incidence of melanoma, the most deadly form of skin cancer, there is currently no national or population-based screening program available. The aim of this CRE is to identify how novel skin imaging technologies can be integrated into the pathway to improve early detection, and ultimately reduce the health and economic burden caused by melanoma skin cancer.
Identification And Erradication Of Pre-malignant B Cells In The Prevention Of Lymphoma
Funder
National Health and Medical Research Council
Funding Amount
$607,771.00
Summary
B Cell Lymphoma is the most frequent type of non-Hodgkin lymphoma in adults and despite improved treatment, 40-50% of patients succumb to their disease. T cells are critical in the in the prevention B cell lymphoma development. In this project we aim to identify the earliest stages of B cell lymphoma and mechanisms of escape from T cell control with the ultimate aim to translate these findings to human studies to improve disease diagnosis, treatment and prognosis.
An In Vitro Pipeline For Liquid Biopsy Biomarkers For Cancer Diagnosis And Therapy
Funder
National Health and Medical Research Council
Funding Amount
$3,764,215.00
Summary
A droplet of blood contains information whether a person has cancer, the stage of the cancer and how their response to treatment. The proposed research will employ ultrasensitive detection technologies to analyse so-called biomarkers released from cancer cells. We will use lab-based models of cancer, generated with a 3D bioprinter, to learn what biomarkers tell us about cancer type and response to drugs. This knowledge is urgently needed for early cancer detection and better cancer treatment.
Novel Prostate Cancer Target For Diagnosis, Imaging, Detection Of Recurrence And Response To Therapy
Funder
National Health and Medical Research Council
Funding Amount
$731,497.00
Summary
This project will generate the critical proof of concept to justify clinical development of a novel biomarker in prostate cancer which would bring significant benefit in terms of differential diagnosis of aggressive disease. The biomarker will be assessed for a functional role in prostate cancer and potential as a therapeutic target and use as a imaging agent in for monitoring disease progression and response to therapy. These investigations will be extended to other common solid tumours.